Likelihood of Approval and Phase Transition Success Rate Model – Rifaximin in Sickle Cell Disease
Powered by
Unlock hidden opportunities in the LoA industry
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model – Rifaximin in Sickle Cell Disease report and make more profitable business decisions.
This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.
Rifaximin in Sickle Cell Disease Drug Details:
Rifaximin (Xifaxan / Normix / Spiraxin / Normiks / Refero / Targaxan / Tixteller / Zaxine / Faxinorm / Xifaxanta / Redactiv / Tixtar / Rifacol / Rifxima / Alpha Normix Forte / Flonorm / Ticstar) is a non-aminoglycoside semi-synthetic antibiotic acts as anti-bacterial agent. It is formulated as tablets, film coated tablets, suspension and granules for oral route of administration and ointment and cream for topical application. It is indicated for the treatment of patients with travellers’ diarrhoea (TD) caused by noninvasive strains of Escherichia coli and reduction in risk of overt hepatic encephalopathy. Xifaxanta tablets are indicated for the treatment of travellers’ diarrhoea that is not associated with any of fever, bloody diarrhoea, eight or more unformed stools in the previous 24 h and occult blood or leucocytes in the stool. Zaxine is indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in patients greater than18 years of age, adjunct in the treatment of hyperammonemia, and also indicated for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.The drug candidate is under development for the treatment of Crohn’s disease, collagenous colitis, chronic intestinal pseudo-obstruction, Alzheimer’s disease, sickle cell disease and symptoms of gastrointestinal distress and pulmonary compromise associated with COVID-19 infection caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and for nonalcoholic fatty liver disease. It was under development for the treatment of irritable bowel syndrome, decompensated cirrhosis and bacterial vaginosis.
Report Coverage
The data is segmented by drug name per indication and shows the current likelihood of approval for the drug compared to the indication benchmark and the industry benchmark.
The Likelihood of Approval data is updated regularly based on events that take place which impact the clinical development process and regulatory considerations. GlobalData’s proprietary machine learning models consider these events in real time, to produce quantitative changes to the LOA and PTSR along with qualitative reasoning why the likelihood of approval has changed.
Quick View – Rifaximin LOA Data | |||||
Report Segments |
|
||||
Drug Name |
|
||||
Administration Pathway |
|
||||
Therapeutic Areas |
|
||||
Key Manufacturers |
|
||||
Drug Development Status |
|
Reasons to Buy
- Precise Likelihood of Approval and Phase Transition Success Rates: Our machine learning and proprietary models provide accurate predictions, helping you gauge the potential success of a drug in the regulatory process.
- Competitive Strategy Planning: Access information on LOA and PTSR for competitors’ drugs, allowing you to plan your clinical development, commercialisation and marketing strategies
- Event-driven Updates: Track event-driven changes in LOA and PTSR benchmarked against indication LOA/PTSR. Get the latest insights to adapt your strategies promptly!
- Well-informed Investment Decisions: This data helps you navigate the dynamic landscape of drug development and regulatory considerations.
Scope
- Drug Details: Drug name, Drug type, Intervention type
- Administration Pathway
- Therapeutic Areas
- Key Manufacturers
- Drug Development Status
This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance.
Frequently asked questions
- Drugs which have been approved in the past 10 years
- Drugs which have failed during clinical development in the past 18 years
- Drugs which are currently in development
- Phase I, Phase II, Phase III, and Pre-Registration development stage
- Drugs must meet one of the following criteria to be included in the model:
- The developer has specified the US as an intended market for approval.
- The developer has not specified any country as an intended market for approval, i.e. the “Drug Geography” is listed as “Global”
- Innovator drugs and biosimilars
- Diagnostics, Imaging Agents, Biomarkers, stents and other drug delivery devices (covered in GlobalData’s Medical Intelligence Center).
- Nutraceuticals, dietary supplements, alternative medicines, imaging agents, radio emitter, transplants, transfusions, fillers, cosmetics, probiotics, antiseptics, antacids, mobilizing agents, veterinary drugs and drugs not seeking approval.
- Generic drugs
- Innovative drugs in Preclinical or Discovery Stage.
- Pipeline drugs sponsored by a Government or Institution.
- Drugs with a specific Drug Geography not the United States.
The probability of a drug ultimately receiving market authorization
The probability of a drug’s advancement to the next stage of clinical development
GlobalData’s Drug-Specific Likelihood of Approval (LoA) calculates the Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA) customized to individual drug. The model uses a combination of Machine Learning (ML) and a GlobalData proprietary algorithm to process data points from the Drugs, Clinical Trials, Regulatory Milestones, Company, and Financial databases.
Inclusion
Data Scope:
Drug Phase Scope:
Drug Geography Scope:
Drug Type Scope:
Entity Type Scope:
Only drugs in development by companies are included in the model.
Exclusion
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745